129 related articles for article (PubMed ID: 1373636)
1. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: outcome and importance of dose intensity.
Husband DJ; Green JA
Eur J Cancer; 1992; 28(1):86-91. PubMed ID: 1373636
[TBL] [Abstract][Full Text] [Related]
2. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours.
Fizazi K; Prow DM; Do KA; Wang X; Finn L; Kim J; Daliani D; Papandreou CN; Tu SM; Millikan RE; Pagliaro LC; Logothetis CJ; Amato RJ
Br J Cancer; 2002 May; 86(10):1555-60. PubMed ID: 12085204
[TBL] [Abstract][Full Text] [Related]
3. [Combination chemotherapy with POMB/ACE (cisplatin, vincristine, methotrexate, bleomycin, actinomycin D, cyclophosphamide, etoposide) in advanced non-seminomatous testicular tumor].
Masuda F; Kawahara M; Asano K; Shirakawa H
Gan To Kagaku Ryoho; 1995 Oct; 22(12):1847-50. PubMed ID: 7574821
[TBL] [Abstract][Full Text] [Related]
4. Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ACE chemotherapy.
Bower M; Newlands ES; Holden L; Rustin GJ; Begent RH
Ann Oncol; 1997 May; 8(5):477-83. PubMed ID: 9233528
[TBL] [Abstract][Full Text] [Related]
5. The management and survival of patients with advanced germ-cell tumours: improving outcome in intermediate and poor prognosis patients.
Bhala N; Coleman JM; Radstone CR; Horsman JM; George J; Hancock BW; Hatton MQ; Coleman RE
Clin Oncol (R Coll Radiol); 2004 Feb; 16(1):40-7. PubMed ID: 14768754
[TBL] [Abstract][Full Text] [Related]
6. POMB/ACE chemotherapy for mediastinal germ cell tumours.
Bower M; Brock C; Holden L; Nelstrop A; Makey AR; Rustin GJ; Newlands ES
Eur J Cancer; 1997 May; 33(6):838-42. PubMed ID: 9291802
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime.
Cullen MH; Harper PG; Woodroffe CM; Kirkbride P; Clarke J
Br J Urol; 1988 Nov; 62(5):454-60. PubMed ID: 2463034
[TBL] [Abstract][Full Text] [Related]
8. Treatment of patients with poor prognosis anaplastic germ cell tumours (AGCT) of the testis and other sites.
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Crawford SM; Holden L
Int J Androl; 1987 Feb; 10(1):301-9. PubMed ID: 2438223
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome in patients with germ cell tumours treated with POMB/ACE chemotherapy: comparison of commonly used classification systems of good and poor prognosis.
Hitchins RN; Newlands ES; Smith DB; Begent RH; Rustin GJ; Bagshawe KD
Br J Cancer; 1989 Feb; 59(2):236-42. PubMed ID: 2467682
[TBL] [Abstract][Full Text] [Related]
10. Current optimum management of anaplastic germ cell tumours of the testis and other sites.
Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Crawford SM; Holden L
Br J Urol; 1986 Jun; 58(3):307-14. PubMed ID: 2424538
[TBL] [Abstract][Full Text] [Related]
11. Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT).
de Bono JS; Paul J; Simpson A; Anthoney A; Kirk D; Underwood M; Graham J; Kaye SB
Br J Cancer; 2000 Aug; 83(4):426-30. PubMed ID: 10945485
[TBL] [Abstract][Full Text] [Related]
12. POMB/ACE chemotherapy for mediastinal germ-cell tumours.
Droz JP
Eur J Cancer; 1997 May; 33(6):809-11. PubMed ID: 9291797
[No Abstract] [Full Text] [Related]
13. Chemotherapy for non-seminomatous germ-cell tumours.
Wilkinson PM
J R Soc Med; 1985; 78 Suppl 6(Suppl 6):43-7. PubMed ID: 2582119
[No Abstract] [Full Text] [Related]
14. Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Fizazi K; Pagliaro L; Laplanche A; Fléchon A; Mardiak J; Geoffrois L; Kerbrat P; Chevreau C; Delva R; Rolland F; Theodore C; Roubaud G; Gravis G; Eymard JC; Malhaire JP; Linassier C; Habibian M; Martin AL; Journeau F; Reckova M; Logothetis C; Culine S
Lancet Oncol; 2014 Dec; 15(13):1442-1450. PubMed ID: 25456363
[TBL] [Abstract][Full Text] [Related]
15. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study.
Gaffan J; Holden L; Newlands ES; Short D; Fuller S; Begent RH; Rustin GJ; Seckl MJ
Br J Cancer; 2003 Nov; 89(10):1849-54. PubMed ID: 14612891
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for metastatic testicular teratoma: long-term follow-up.
Dearnaley DP; Horwich A; A'Hern R; Nicholls J; Jay G; Hendry WF; Peckham MJ
Eur J Cancer; 1991; 27(6):684-91. PubMed ID: 1712606
[TBL] [Abstract][Full Text] [Related]
17. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
[TBL] [Abstract][Full Text] [Related]
18. The long-term outcome of patients who relapse after chemotherapy for non-seminomatous germ cell tumours.
Ledermann JA; Holden L; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD; Brampton M
Br J Urol; 1994 Aug; 74(2):225-30. PubMed ID: 7522874
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for ovarian germ cell tumours.
Bower M; Fife K; Holden L; Paradinas FJ; Rustin GJ; Newlands ES
Eur J Cancer; 1996 Apr; 32A(4):593-7. PubMed ID: 8695258
[TBL] [Abstract][Full Text] [Related]
20. The effect of intensity of administered treatment on the outcome of germ cell tumours treated with POMB/ACE chemotherapy.
Crawford SM; Newlands ES; Begent RH; Rustin GJ; Bagshawe KD
Br J Cancer; 1989 Feb; 59(2):243-6. PubMed ID: 2467683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
